HSCI scientists work together across Harvard’s schools, centers, and teaching hospitals, harnessing the power of stem cells to cure human diseases.
Stem cell research has unlimited potential to produce treatments for human diseases. It gives us unprecedented insights into how human beings grow, age, and repair. This knowledge is empowering us to transform human health for the better.
To achieve this ambitious goal we leverage the unique strengths of Harvard, which is at the center of the most intense concentration of biomedical and biopharmaceutical research in the world. We provide fertile ground for more than 325 research faculty and their labs, across Harvard's many sites, to share knowledge and pursue bold new ideas.
Together, we are accelerating research out of the lab and into the clinic, where it can make a lasting difference in people’s lives.
Our research bridges the gaps in traditional funding to encourage bold thinking, create focus, and launch scientific careers. Through disease-specific programs, our community focuses on some of the most prevalent, devastating conditions for which stem cell research holds promise.
Centers and cores
Our members have access to Harvard core facilities to support their research, including:
- iPS Core Facility
- HSCI Therapeutic Screening Center
- HSCI Center for Stem Cell Bioinformatics
- Center for Human Cell Therapy (CHCT)/Trans Lab
- Flow cytometry cores at Boston Children's Hospital, Joslin Diabetes Center, Massachusetts General Hospital, and the Harvard University Department of Stem Cell and Regenerative Biology
- Production of clinical-grade cellular therapy products through the Connell O’Reilly Cell Manipulation Core Facility (DF/HCC) at DFCI
Since 2004, HSCI scientists have been exploring ways to harness the power of stem cells to heal patients, supported by families, foundations, investors, and companies that share our vision. HSCI research has helped make bone marrow transplants safer and easier for donors and patients. It has led to clinical trials of treatments to restore eyesight in people with corneal or retinal injury. Soon, we will be able to liberate diabetes patients from life-long treatment régimes, and their families from constant worry.
But this is just the beginning.
HSCI helps keep ideas flowing from the bench into the clinic, and on to the marketplace. The success of our translational work is reflected in the outputs of HSCI scientists, who publish new findings in over 25 scientific papers every month and have spurred the launch of 30 biotechnology startup companies.
The achievements of HSCI scientists spring from collaborations that go well beyond Harvard schools, institutes, and hospitals. Our interactions with biomedical companies such as GSK, Astra Zeneca, Roche, and Johnson & Johnson, among others, have all helped us lay essential groundwork for the development of applications to benefit patients.
For example, the Harvard Fibrosis Network is a collaborative program at HSCI that partners with companies such as Boehringer Ingelheim, Bristol Meyers Squibb, and others. The program enables research into diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, cardiac disease, and nonalcoholic steatohepatitis.